Publications

  1. Torres, J.V., Yoshioka, N. and Atassi, M.Z. Antigenic Regions on the B Chain of Human Chorionic Gonadotropin and Development of Hormone Specific Antibodies.  Immunological Investigations 16:607-618.  1987
  2. Torres, J.V., Wyde, P.R. and Atassi, M.Z. Cytotoxic T Lymphocyte Recognition Sites on the Influenza Virus Hemagglutinin.  Immunology Letters 19:49-54.  1988
  3. Atassi, M.Z., Torres, J.V. and Wyde, P.R. Cytotoxic and Helper T Lymphocyte Responses to Antibody Recognition Regions on Influenza Virus Hemagglutinin.  Advances In Experimental Medicine and Biology 251:49-64.  1989
  4. Werner, L.L., Malley, A., Torres, J.V., Leung, C.Y., Kwang, H.S. and Benjamini, E. Synthetic Peptides of Envelope Proteins of Two Different Strains of Simian AIDS Retrovirus (SRV-1 and SRV-2) Represent Unique Antigenic Determinants for Serum Neutralizing Antibodies.  Molecular Immunology 27(11):1103-1111.  1990
  5. Werner, L.L., Torres, J.V., Leung, C.Y., Kwang, H.S., Malley, A. and Benjamini, E. Immunobiological Properties of a Recombinant Simian Retrovirus-1 Envelope Protein and a Neutralizing Monoclonal Antibody Directed Against It.  Molecular Immunology. 28:819-826.  1991
  6. Torres, J.V., Werner, L.L., Malley, A. and Benjamini, E. The Induction of Neutralizing Antibodies by Synthetic Peptides of the Envelope Protein of Type D Simian Retrovirus-1 (SRV-1).  Molecular Immunology.  28:907-913.  1991
  7. Malley, A., Werner, L.L., Benjamini, E., Leung, C.Y., Torres, J.V., Pangaras, N., Shiigi, S. and Axthelm, M. Characterization of T and B Cell Epitopes of a Simian Retrovirus (SRV-2) Envelope Protein.  Journal of Medical Primatology.  20:177-181.  1991
  8. Torres, J.V., Werner, L.L., Malley, A. and Benjamini, E. Neutralization Epitope in the Envelope Glycoprotein of Simian Retrovirus-1 (SRV-1) and Identification of the Virus Receptor.  Journal of Medical Primatology.  20:218-221.  1991
  9. Benjamini, E., Torres, J.V., Werner, L.L. and Malley, A. Isolation and Characterization of the Neutralizable Epitope of Simian Retrovirus-1 (SRV-1) and of the Cell Receptor for the Virus. Proceedings of the Sixth International Symposium on the Immunobiology of Protein and Peptides.  In: Atassi, M.Z. ed., Advances in Experimental Medicine and Biology, Vol.303, Plenum Press, NY and London. pp.71-77.  1991
  10. Van Kuyk, R.W., Acevedo, R.A., Torres, J.V., Levy, N.B., Planelles, V., Munn, R.J., Unger, R.E., Gardner, M.B., and Luciw, P.A.  Characterization of Rhesus Macaque B Lymphoblastoid Cell Lines Infected with Simian Type D Retrovirus.  AIDS Research and Human Retroviruses. 7:899-909.  1991
  11. Malley, A., Torres, J.V., Benjamini, E., Pangares, N., and Axthelm, M.  Characterization of T Cell Epitopes on the Envelope Glycoprotein of Simian Retrovirus 1 and 2 (SRV-1 and SRV-2) in Several Mouse Strains.  Molecular Immunology. 29:999-1004.  1992
  12. Torres, J.V., Malley, A., Banapour, B., Anderson, D.E., Axthelm, M.K., Gardner, M.B., and Benjamini, E.  An Epitope on the Surface Envelope Glycoprotein (gp130) of Simian Immunodeficiency Virus (SIVmac) Involved in Viral Neutralization and T Cell Activation.  AIDS Research and Human Retroviruses. 9:423-428.  1993
  13. Malley, A., Pangares, N., Mayo, S.K., Zeleny-Pooley, M., Torres, J.V., Benjamini, E., and Axthelm, M.K.  Type D SRV-2 Virus-specific CD8+ and CD4-CD8- T Cells that Regulate Virus-induced T Cell Proliferation in Celebes Macaques.  Journal of Medical Primatology.  22:80-85.  1993
  14. Torres, J.V., Anderson, D.E., Malley, A., Banapour, B., Axthelm, M.K., Benjamini, E., and Gardner, M.B.  SIV Envelope Glycoprotein Epitopes Recognized by Antibodies from Infected or Vaccinated Rhesus Macaques.  Journal of Medical Primatology. 22:129-137.  1993
  15. Haynes, B.F., Torres, J.V., Langlois, A.J., Bolognesi, D.P., Gardner, M.B., Scearce, R.M., Jones, D.M., Moody, M.A., McDanal, C., and Matthews, T.J.  Induction of HIVMN Neutralizing Antibodies in Primates Using a Prime-boost Regimen of Hybrid Synthetic gp120 Envelope Peptides.  Journal of Immunology.  151:1646-1653.  1993
  16. Haynes, B.F., Yasutomi, Y., Torres, J.V., Gardner, M.B., Langlois, A.J., Bolognesi, D.P., Matthews, T.J., Scearce, R.M., Jones, D.M., Moody, M.A. et al.  Use of Synthetic Peptides in Primates to Induce High-titered Neutralizing Antibodies and MHC Class I-restricted Cytotoxic T Cells Against Acquired Immunodeficiency Syndrome Retroviruses: an HLA-Based Vaccine Strategy.  Transaction of the Association of American Physicians.  106:33-41.  1993
  17. Anderson, D.E., Malley, A., Benjamini, E., Gardner, M.B., and Torres, J.V., Hypervariable Epitope Constructs (HECs) as a Means of Accounting for Epitope Variability.  Vaccine. 12:736-740.  1994
  18. Kwang, J., and Torres, J.V.  Oligopeptide-Based Enzyme Immunoassay for Ovine Lentivirus Antibody Detection.  Journal of Clinical Microbiology 32:1813-1815.  1994
  19. D'Souza, M.P., Kent, K., Thiriart, C., Collignon, C., Milman, G., et. al.  International Collaboration Comparing Neutralization and Binding Assays for Monoclonal Antibodies to Simian Immunodeficiency Virus.  AIDS Research and Human Retroviruses 9:415-422.  1995
  20. Mitchell, W.M., Torres, J.V., Johnson, P.R., Hirsch, V., Yilma, T., Gardner, M.B., and Robinson, Jr., W.E.  Antibodies to the Putative SIV Infection-enhancing Domain Diminish Beneficial Effects of an SIV gp160 Vaccine in Rhesus Macaques.  AIDS 9:27-34.  1995
  21. Kraiselburd, E.A., and Torres, J.V.  Properties of Virus-like Particles Produced by SIV Chronically Infected Human Cell Clones.  Cellular and Molecular Biology 41:S41-S52.  1995
  22. Weinberg, J., Liao, H.X., Torres, J.V., Matthews, T.J., Robinson, J., and Haynes, B.F.  Identification of a Synthetic Peptide that Mimics an HIV Glycoprotein 120 Envelope Conformational Determinant Exposed Following Ligation of Glycoprotein 120 by CD4.  AIDS Research and Human Retroviruses, 13:657-664.  1997
  23. Meyer, D., Anderson, D.E., Gardner, M.B., and Torres, J.V.  Hypervariable Epitope Constructs Representing Variability in Envelope Glycoprotein of SIV Induce a Broad Humoral Immune Response in Rabbits and Rhesus Macaques.  AIDS Research and Human Retroviruses. 14 (9): 751-760.  1998
  24. Anderson, D. and Torres, J.V. SRV Receptor and Neutralization Mechanism by Antibodies to the Envelope Glycoprotein. Viral Immunology, 12(1):47-56.  1999
  25. Vu, HM, Myers, D, de Lorimier, R, Matthews, TJ, Moody, MA, Heinly, C, Torres, JV, Haynes, BF and Spicer, L. Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived From Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-induced Anti-HIV Neutralizing Antibodies. Journal of Virology, 73(1):746-750.  1999
  26. Muñoz, J.F., Salmen, S., Carlos, M.P., Berrueta, L.R., Cova, J.A., Donis, J.H., Hernández, M.R, and Torres, J.V.  Effect of HIV-1 on Intracellular Activation and Superoxide Production by Neutrophils.  The Journal of Infectious Diseases, 180(1):206-210.  1999
  27. Meyer, D. and Torres, J.V.  Induction of Cytotoxic and Helper T Cell Responses by Modified Variability Peptides. Viral Immunology, 12(2):117-129.  1999
  28. Meyer, D. and Torres, J.V.  Hypervariable Epitope Construct: A Synthetic Immunogen That Overcomes MHC Restriction of Antigen Presentation.  Molecular Immunology, 36(10): 631-637.  1999
  29. Carlos, MP, Yamamura, Y., Diaz-Mitoma F. and Torres, JV. Antibodies from HIV positive and AIDS Patients Bind to an HIV Envelope Variable Antigen Vaccine.  Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 22(4): 317-324.  1999
  30. Carlos, M.P., Anderson, D.E., Gardner, M.B. and Torres, J.V. Immunogenicity of a Vaccine Preparation Representing the Variable Regions of the HIV-1 Envelope Glycoprotein.  AIDS Research and Human Retroviruses, 16(2): 153-161.  2000
  31. Balaban, N, Singh, B, Goldkorn, T, Rasooly, A, Torres, J.V. and Uziel, O. Activation and Inhibition of the Staphylococcal AGR system (technical comment). Science, 287:391a.  2000.
  32. Leung, NJ, Aldovini, A, Young, R, Jarvis, MA, Smith JM, Meyer D, Anderson, DE, Carlos, MP, Gardner, MB and Torres, JV.  The Kinetics of Specific Immune Responses in Rhesus Monkeys Inoculated with Live Recombinant BCG Expressing SIV Gag, Pol, Env, and Nef Proteins. Virology, 268:94-103.  2000
  33. Muñoz, J.F., Salmen, S., Berrueta, L.R., Carlos, M.P., and Torres, J.V.  Effect of Plasma HIV-1 RNA Levels on Neutrophil Oxidative Burst.  The Journal of Infectious Diseases, 181(3): 1214-16.  2000
  34. Smith, J.M., N. Leung, and Torres J.V. Preparation and Induction of Immune Responses by a DNA AIDS Vaccine.  Viral Immunology, 13(3): 343-351.  2000
  35. Miyagi,T., Chuang, LF., Doi, RH., Carlos, MP., Torres, JV. and Chuang, RY. Morphine Induces Gene Expression of CCR5 in Human CEMx174 Lymphocytes.  Journal of Biological Chemistry.  275(40): 31305-31310.  2000
  36. Balaban, N., Collins, V., Cullor, J.S., Hume, E.B., Medina-Acosta, E., O'Callaghan, R.,Vieira da Motta, O., Rossitto, P.V., Serafim da Silveira L., Shirtliff, M.E., Tarkowski, A., and Torres, J.V. Prevention of Diseases Caused by Staphylococcus aureus Using the Peptide RIP. Peptides, 21 1301-1311.  2000
  37. Gov, Y., Bitler, A., Dell’Acqua, G., Torres, J.V., and Balaban, N.  RNAIII inhibiting peptide (RIP), a global inhibitor of Staphyloccocus aureus pathogenesis:structure and function. Peptides, 22(10), 1609-1620, 2001
  38. Hel Z, Nacsa J, Kelsall B, Tsai WP, Letvin N, Parks RW, Tryniszewska E, Picker L, Lewis MG, Edghill-Smith Y, Moniuszko M, Pal R, Stevceva L, Altman JD, Allen TM, Watkins D, Torres JV, Berzofsky JA, Belyakov IM, Strober W, Franchini G.  Impairment of Gag-Specific CD8(+) T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques. Journal of Virology. Dec;75(23):11483-95. 2001
  39. Anderson, D.E., Carlos, M.P., Nguyen, L., and Torres, J.V. Overcoming Original (Antigenic) Sin, Clinical Immunology, 101(2), 152-157, 2001
  40. Smith, J.M., and Torres J.V. A Retroviral DNA Vaccine Vector. Viral Immunology, 14(4), 339-348, 2001
  41. Suzuki S, Carlos MP, Chuang LF, Torres JV, Doi RH, Chuang RY. Methadone induces CCR5 and promotes AIDS virus infection. FEBS Lett. May 22; 519(1-3):173-177, 2002
  42. MP Carlos, Y Yamamura, Q Vu, DE Anderson, F Diaz-Mitoma and JV Torres. Immune Evasion Strategy of HIV-1 Directed Against the Hypervariable Regions V1 through V3 of the Envelope Glycoprotein.  Proceedings of the XIV International AIDS Conference 2002.  C708F2505, 241-245, 2002
  43. Rendon-Maldonado J, Espinosa-Cantellano M, Soler C, Torres JV and Martinez-Palomo A.  Trichomonas vaginalis:  In vitro attachment and internalization of HIV-1 and HIV-1 infected lymphocytes.  Journal of Eukaryotic Microbiology, 50(1): 43-48, 2003
  44. Medina AL, Cova JA, Vielma RA, Pujic P, Carlos MP and Torres JV. Immunological and chemical analysis of proteins from Eisenia foetida earthworm.  Food and Agricultural Immunology, 15(3-4): 255-263, 2003
  45. Torres, JV.  Vaccine Design for Emergent Viruses.  Informaceutico, 11(1): 17-20, 2004
  46. Carlos MP, Yamamura Y, Vu Q, Conzen K, Anderson DE and Torres JV. Humoral immunity to immunodominant epitopes of Hepatitis C virus in individuals infected with genotypes 1a or 1b. Clinical Immunology, 111: 22-27, 2004
  47. Reddy KJ, Banapour B, Anderson DE, Lee SH, Marquez JP, Carlos MP and Torres JV. Induction of immune responses against human papilloma viruses by hypervariable epitope constructs.  Immunology, 112: 321-327, 2004
  48. Anderson DE, Llenado RA and Torres JV. Humoral Immunity and the Evolution of HIV-2. Viral Immunology, 17(3): 436-439, 2004
  49. Anderson DE, Singapuri A, Kang KH, Montefiori DC and Torres JV. Timing of Retroviral Infection Influences Anamnestic Immune Response in Vaccinated Primates. Viral Immunology, 18(4): 689-694, 2005
  50. Azizi, A., Anderson, D.E., Torres, J.V., Ogrel, A., Ghorbani, M, Soare, C, Gee, K, Sandstrom, P., Fournier, J and Diaz-Mitoma, F. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine, Retrovirology 6 (S3), 330, 2009
  51. Azizi, A., Sirskyj, D., Saad, A., Ogrel, A., Le, T, Soare, C, Anderson, D.E., Torres, J.V., and Diaz-Mitoma, F. Induction of Broad Cross-Subtype Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques, The Journal of Immunology, 180 (4):2174-2186, 2008
  52. Kang KH, Yamamura Y, Carlos MP, Karvelas N, Kim IS, Sunkara D, Rivera R, Gardner MB, Anderson DE, Diaz-Mitoma F, Torres JV and Marquez JP. Synthetic Antigens Representing the Antigenic Variation of Human Hepatitis C Virus, Viral Immunology, 23 (5) 1-12, 2010
  53. Ghunaim H, Kumar A, Torres JV, Diaz-Mitoma F, and Azizi, A. An Immunological Comparison between Lipidated and Non-Lipidated Multivalent HIV-1 Peptides Representing Gp120 and Gag Hypervariable Regions, Vaccine 29 (35) 5950-5958, 2011
  54. Marquez JP, Rivera R, Kang KH, Gardner MB, and Torres JV.  Human Papillomavirus Immunogen That Provides Protective Tumor Immunity and Induces Tumor Regression, Viral Immunology, 25 (2) 1-12, 2012
  55. Rivera, R., K.H. Kang, D.E. Anderson, J.P. Marquez, M.B. Gardner and J.V. Torres. Anamnestic Immune Response Eight Years After Immunization of Primates With a Multivalent HIV-1 Gp120 Variable Peptide Vaccine. Am. J. Immunol., 9: 30-35, 2013

In Preparation

  1. Carlos MP, Mendelev MP, Kun E and Torres JV.  Inhibition of HIV replication and proviral DNA integration by DIME.
  2. Cova JA, Carlos MP, Dewey K, Lonnerdal B and Torres JV. Inactivation of Human Immunodeficiency Virus type 1 in Human Breast Milk.
  3. Cova JA, Carlos MP, Dewey K, Lonnerdal B and Torres JV.  Chemical Inactivation of Human Immunodeficiency Virus type 1 in Human Breast Milk.

Abstracts (Selected)

  1. Torres, J.V. and Lee, C.L.  A monoclonal antibody specific for a tumor associated antigen from colon carcinoma.  American Association of Cancer Research, Houston, TX.  1984
  2. Lee, C.L., Torres, J.V., Tan, M.H., Li, C.Y., Tseng, M.H., and Chu, T.M.  Monoclonal antibody specific for human colon adenocarcinoma.  Proceedings of AACR, vol. 26, p. 319.  1985
  3. Torres, J.V., Yoshioka, N. and Atassi, M.Z.  Human chorionic gonadotropin antigen regions and development of hormone specific antibodies.  FASEB, 7243, Las Vegas, NV.1988 
  4. Torres, J.V., Wyde, P.R. and Atassi, M.Z. Immune recognition of several areas at the surface of the influenza virus hemagglutinin molecule, FASEB, New Orleans, Louisiana.1989
  5. Werner, L.L., Torres, J.V., Kwang, H.S., Leung, C.Y., and Benjamini, E.  The immunobiological properties of a recombinant SRV-1 envelope protein and a neutralizing monoclonal antibody directed against it.  Eighth Annual Symposium on Nonhuman Primate Models for AIDS.  New Orleans, Louisiana. 1990
  6. Malley, A., Werner, L., Benjamini, E., Leung, C.Y., Torres, J., Pangares, N., Shiigi, S., and Axthelm, M.  Characterization of T and B cell epitopes of a simian retrovirus (SRV-2) envelope protein.  Eighth Annual Symposium on Nonhuman Primate MOdels for AIDS.  New Orleans, Louisiana. 1990
  7. Torres, J.V. and Benjamini, E.  SIV neutralization by antibodies.  Ninth annual AIDS investigators' meeting.  Program and Abstracts.  San Francisco, California. 1992
  8. Gardner, M.B., Torres, J.V.  Characterization of immunoprotective B cell epitopes in the SIVmac envelope.  Ninth annual AIDS investigators' meeting.  Program and Abstracts.  San Francisco, California.  1992
  9. Hart, M.K., Searce, R.M., Jones, D.M., Mathews, T.J., Weinhold, K.,  Langlois, A.J., Moody, M.A., Gardner, M.B., Torres, J.V., Arthur, L.O., Bolognesi, D.P., and Palker, T.J.  HIV synthetic peptides containing T and B cell epitopes as vaccine candidates.  Keystone Symposia on molecular & cellular biology.  Keystone, Colorado.  Journal of Cellular Biochemistry. Suppl. 16E. Q027, p.10.  1992
  10. Torres, J.V., Anderson, D.E., Banapour, B., Benjamini, E., and Gardner, M.  Antigenic sites involved in protection of vaccinated monkeys and the role of a new neutralization epitope in the envelope glycoprotein of SIV.  Keystone Symposia on molecular & cellular biology.  Keystone, Colorado.  Journal of Cellular Biochemistry.  Suppl. 16E. p.102.               1992
  11. Haynes, B.F., Torres, J.V., Langlois, A.J., Bolognesi, D.P., Gardner, M.B., Palker, T.J., Scearce, R.M., Jones, D.M., Moody, M.A., McDanal, C., and Mathews, T.J.  Induction of broadly cross-reactive HIV neutralizing antibodies in primates using a prime boost regimen of hybrid synthetic gp120 envelope peptides.  Advances in AIDS Vaccine Development, 5th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS.  Chantilly, Virginia.  August 30-September 3. 1992
  12. Malley, A., Pangares, N., Mayo, S.K., Zeleny-Pooley, M., Torres, J.V., Benjamini, E., and Axthelm, M.K.  A Type D SRV-2 virus-specific CD8 T cell that regulates virus-induced T cell proliferation in Celebes macaques.  Tenth Annual Symposium on Nonhuman Primate Models for AIDS.  San Juan, Puerto Rico.  1992
  13. Gardner, M.B., Yilma, T., Jennings, M., Marthas, M., Giavedoni, L., Torres, J., Pederson, N., and Luciw, P.  Vaccine and pathogenesis studies in the SIV macaque model.  Laboratory of Tumor Cell Biology Annual Meeting.  Bethesda, Maryland, August 9-15.1992
  14. Haynes, B.F., Yasutomi, Y., Torres, J.V., Gardner, M.B., Langlois, A.J., Bolognesi, D.P., Matthews, T.J., Scearce, R.M., Jones, D.M., Moody, M.A., McDanal, C., Heinley, C., Bergamo, B., Palker, T.J., and Letvin, N.L.  Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I restricted cytotoxic T cells against AIDS retroviruses: an HLA-based vaccine strategy for primate retroviruses.  AFCAR Clinical Research Meeting.  1993
  15. Torres, J.V., Leung, N., Vermazen, H., Jarvis, M., Anderson, D., Luciw, P., Aldovini, A., Young, R., and Gardner, M.B.  Combination vaccine approach for the prevention and treatment of infection by SIV and HIV.  22nd Keystone Symposia on Molecular and Cellular Biology.  Albuquerque, New Mexico.  Journal of Cellular Biochemistry. Suppl.17E, Q556, p.81, March.  1993
  16. Torres, J.V., Malley, A., Anderson, D.E., and Gardner, M.B.  Identification of a strong neutralizing epitope in the V4 region of SIVmac.  IXth International Conference on AIDS.  Berlin, Germany, June 7-11.  1993
  17. Kraiselburd, E.N., Malaga, C., Beltran, M., Leung, N., and Torres, J.  Characterization of defective viruses produced by an SIV chronically infected cell clone.  23rd Annual Keystone Symposia on Molecular and Cellular Biology, Prevention and Treatment of AIDS, Hilton Head Island, South Carolina. Journal of Cellular Biochemistry, Abstract Supplement 18B, p. 135.  1994
  18. Leung, N.J., Anderson, D.A., Jarvis, M.A., Cotterman, R.F., Vermazen, H.L., White, A., Aldovini, A., Young, R., Gardner, M.B., and Torres, J.V.  Humoral and cellular responses to a HEC/rBCG combination vaccine against SIV.  23rd Annual Keystone Symposia on Molecular and Cellular Biology, Prevention and Treatment of AIDS, Hilton Head Island, South Carolina.  Journal of Cellular Biochemistry, Abstract Supplement 18B, p.157.1994
  19. Torres, J.V.  "Hypervariable epitope constructs (HECs) as a means of accounting for epitope variability".  Universitywide AIDS Research Program, 11th Annual AIDS Investigators' Meeting, San Francisco, CA, March 29-30.  1994
  20. Torres, J.V.  "Humoral and cellular responses to a HEC/rBCG combination vaccine against SIV and HIV".  Universitywide AIDS Research Program, 11th Annual AIDS Investigators' Meeting, San Francisco, CA, March 29-30. 1994
  21. Torres, JV., Leung, NJ., Vermazen, H.  Humoral and cellular immune responses to a combination vaccine against AIDS.  May 10.  1994
  22. Kraiselburd, E., Smith, J., Leung, N., Salaman, A., and Torres, J.V.  "Characterization of SIVsmB7:  a biologically cloned deletion mutant of SIVsmH3".  Keystone Symposia. Colorado. April 17-23, 1995
  23. Kraiselburd, E., Salaman, A., Beltran, M., Malaga, C., Kessler, M., Leung, N., and Torres, J.V.  "Properties of an SIV deletion mutant derived from CEMX174 cells chronically infected with SIVsmH3".  12th Annual Symposium on Nonhuman Primate Models for AIDS, Boston, MA, October 12-15.  1994
  24. Bassler, K.D., Montbriand, P., Torres, J.V., Malone, J.G., Luciw, P.A., Bennett, M.J., and Malone, R.W.  "Development and testing of intramuscular and mucosal genetic vaccines".  Regional Meetings, American Federation for Clinical Research.''  1994
  25. Torres, J.  Vaccine trials.  HIV surrogate markers workshop: linking basic science and patient care, October 23-25, 1994, Aylmer, Quebec, Canada.  Abstract 2.3, page 4.  1995
  26. Torres, J.V.  Construcción de Vacunas: El Caso del Sida".  XXVII Congresso Nacional de Farmacéuticas, 22-26 October, Merida, Yucatan, Mexico, page 51.  1995
  27. Kraiselburd, E, Salaman, A., Beltran, M., Kessler, M., Smith, J, and Torres, J.V.  Partial characterization of biologically cloned SIVsm VLP.  13th Annual Symposium on Nonhuman Primate Models for AIDS, November 5-8, 1995, Monterey, CA.  Abstract #133, p. 215.  1995
  28. Leung, N.J., Smith, J., Aldovini, A., Young, R., Gardner, M.B. and Torres, J.V.  SIV- specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing Gag, Pol, Env and Nef proteins.  13th Annual Symposium on Nonhuman Primate Models for AIDS, November 5-8, 1995, Monterey, CA.  Abstract #135, p. 217.1995
  29. Meyer, D., Anderson, D., Gardner, M.B. and Torres, J.V.  Hypervariable epitope constructs as a means of accounting for epitope variability and overcoming MHC restriction.   13th Annual Symposium on Nonhuman Primate Models for AIDS, November 5-8, 1995, Monterey, CA.  Abstract #139, p. 221.  1995
  30. Carlos, M.P., Brakel, J. B. and Torres, J.V. HIV-1 Envelope Glycoprotein Variability and the Immune Response to a Synthetic Immunogen. NCASM Annual Spring Meeting, April 27, San Jose, CA.  1996
  31. Brakel, J., Carlos, M.P., Rodriguez, Y. and Torres, J.V.  Kaposi’s Sarcoma Patients Produce Antibodies which Bind to a New Synthetic Vaccine Representing the Antigenic Variation of HIV-1.  UC Davis Cancer Program Second Annual Cancer Research Symposium, September 28, Sacramento, CA.  Poster # 53.1996
  32. Smith, J. and Torres, J.V.  Use of a DNA vaccine for the induction of immune responses against SIV.  Annual Research Symposium Microbiology Graduate Group, October 8, Davis, CA.  1996
  33. Carlos, M.P., Brakel, J. and Torres, J.V.  A Vaccine To Immunize Against The HIV-1 Variability.  3rd International Conference on Engineered Vaccines for Cancer and AIDS, October 9-14, Hilton Head Island, South Carolina.  Abstract # 100. 1996
  34. Kraiselburd, E., Salamán, A., Smith, J. and Torres, J.V.   Lower Viremia In Rhesus Macaques Following Vaccination With A Noninfectious SIV Virus-Like Particle, 14th Symposium on Nonhuman Primate Models for AIDS, October 22 - 26,  Portland, Oregon. 1996
  35. Carlos, M.P., Brakel, J. and Torres, J.V.  Immune Response to a Synthetic Immunogen which Represents the Variability of the HIV-1 envelope Glycoprotein Major Epitopes.  14th Symposium on Nonhuman Primate Models for AIDS, October 22 - 26, Portland, Oregon.  1996
  36. D.A. Meyer, D.E. Anderson, M.B. Gardner and J. Torres "Synthetic peptide immunogens can mimic SIV envelope heterogeneity" Potchefstroom South Africa, October 1, 1998
  37. Carlos MP, Cardernas SE, Sanchez KH and Torres JV.  Vaccine representing HIV envelope hypervariable epitopes.  Journal of Medical Primatology, Volume 27(Issues 2/3, April/June):159. 1998
  38. Wong H, Carlos MP, Nguyen M, Ramirez F, Chiang H and Torres JV.  Vaccine component against influenza virus.   80th Annual Meeting of the American Association for the Advancement of Science, Pacific Division, San Francisco, California. June 19-23,1999. Poster No. 11.
  39. Carlos MP. Development of HIV Vaccines in Non-Human Primates. 67th Philippine Veterinary Medical Association Annual Convention.  Bacolod Convention Plaza, Negros Occidental, Philippines.  February 16-18, 2000
  40. Carlos MP, Anderson DE and Torres, JV.  Hepatitis C virus vaccine that accounts for antigenic variability.  Immunology 2000.  Block Symposium: Vaccine Strategies against Microbial Pathogens.  Seattle, Washington.  May 13, 2000. 42.7.
  41. Anderson DE, Carlos MP and Torres, JV.  Overcoming Original (antigenic) sin.  Immunology 2000.  Block Symposium:  Vaccine Strategies against Microbial Pathogens.  Seattle, Washington.  May 13, 2000.  40.16.
  42. Carlos MP, Anderson DE and Torres JV.  Development of Human Hepatitis C Vaccine.  SILCIBIO-Nocardiae 2000.  Third Symposium of Latin American Scientists in Biomedical Research and Second International Conference on the Biology of Nocardiae.  School of Medicine, University of California, Davis.  Davis, California.   September 11-15, 2000.
  43. Cova JA, Carlos MP, Dewey K, Lonnerdal B and Torres, JV.  Inactivation of Human Immunodeficiency Virus Type 1 in human breast milk by antiviral compounds. SILCIBIO-Nocardiae 2000.  Third Symposium of Latin American Scientists in Biomedical Research and Second International Conference on the Biology of Nocardiae. School of Medicine, University of California, Davis.  Davis, California.   September 11-15, 2000.
  44. Carlos MP, Anderson DE and Torres, JV.  Design of a Vaccine against Hepatitis C Virus.  Sixth Annual Cancer Research Symposium. University of California Davis Cancer Center. Sacramento, California. October 6-7, 2000.  17.
  45. Carlos MP, Anderson DE and Torres JV.  HIV and AIDS.  California Associations for Medical Laboratory Technology, Continuing Medical Education (CME, 3 Units). Sacramento, CA. February 11, 2001.
  46. Anderson DE, Carlos MP and Torres JV.  Vaccination to elicit broadly reactive humoral immunity upon viral infection.  Federation of Clinical Immunology Societies (FOCIS) Annual Meeting. Boston, MA. May 4-7, 2001.  Abstract No. 206.
  47. Carlos MP, Anderson DE, Yasuhiro Y and Torres JV.   Immunotherapeutic vaccine against Hepatitis C virus infection inducing a broadly reactive immune response.  Federation of Clinical Immunology Societies (FOCIS) Annual Meeting. Boston, MA. May 4-7, 2001. Abstract No. 332.
  48. Carlos MP, Anderson DE, Yasuhiro Y, Gardner MB and Torres JV.   Multivalent AIDS vaccine component.  Antiviral Therapy. 6:S133.  2001.
  49. Anderson DE, Carlos MP and Torres JV.  Vaccination to elicit broadly reactive humoral immunity upon viral infection.  Clinical Immunology. 99(1):170-171.  2001.
  50. Banapour B, Reddy J, Anderson DE, and Torres, JV.  Development of a cancer vaccine against human papillomavirus (HPV).   Seventh Annual Cancer Research Symposium. University of California Davis Cancer Center. Sacramento, California. October 12-13, 2001
  51. Carlos MP, Anderson DE, Yamamura, Y, Banapour B, Yim A. and Torres, JV.  A vaccine approach against hepatitis C virus infection inducing a broadly reactive immune response.  Seventh Annual Cancer Research Symposium. University of California Davis Cancer Center. Sacramento, California. October 12-13, 2001 #29
  52. Ghorbani, M., Aucoin S., Giulivi A., Carlos M.P., Torres, J.V., Anderson, D.E., and Diaz-Mitoma, F.J.  Predominance of IgG1 against Hepatitis C by a combination of DNA plamid, Core E1/E2 protein and montanide.  Fifth Annual Conference on Vaccine Research.  Bethesda, Maryland. May 6-8, 2002. Abstract 02-A-115NFID.
  53. Anderson DE and Torres JV.  Vaccination to elicit broadly reactive humoral immunity upon viral infection.  8th  National Symposium on Basic Aspects of Vaccines.  Bethesda, MD.  May 1-3, 2002.
  54. Carlos MP, Anderson DE, Vu QK, Conzen K, Yim A, Diaz-Mitoma F, Yamamura Y and Torres, JV.  A vaccine to circumvent the genetic variation and immune selection pressure of hepatitis c virus.  Clinical Immunology. 103 (3):S101.  2002.
  55. Anderson DE, Banapour BB, Chao DK, Anderson RC, Parsa AT, Bruce JN and Torres, JV.     Immunological analysis of ex vivo brains trumors and strategies for immunotherapy.  Clinical Immunology. 103 (3):S89-S90.  2002.
  56. Carlos MP, Yamamura YY, Anderson DE, Diaz-Mitoma, Fand Torres, JV.  Selective B-cell and T-cell Immune Pressure Directed Aginst the Hypervariable Regions V1-V5 of the Envelope Glycoprotein of HIV-1. XIV International AIDS Conference.  Barcelona, Spain. July 7-12, 2002. Abstract No.  A10148
  57. Vu QK, Yamamura Y, Carlos MP, and Torres JV. Comparison and Characterization of Antibody Responses in Hepatitis C Infected Patients. UC Davis Cancer Center, Sacramento. September 2002.
  58. Carlos MP. Differential immune responses elicited by genotypes 1a and 1b of hepatitis C virus implicates a vaccine approach preventing infection and establishment of hepatocellular carcinoma. UC Davis Cancer Center, Sacramento. September 2002.
  59. Reddy KJ, Banapour BD, Lee SH, Anderson DE, and Torres JV. Development of a preventive vaccine against cervical cancer. UC Davis Cancer Center, Sacramento. September 2002.
  60. 2003. Vaccine-induced immune response against Human Papillomavirus (HPV) in a cervical carcinoma animal model. Marquez M. JP, Anderson E. David, Rivera Rebecca and Jose V. Torres.
  61. Ninth Annual Cancer Research Symposium. UCDavis Cancer Center.
  62. 2004. Immunotherapy-induced cancer regression in a cervical carcinoma animal model. Marquez M. JP, Dodd Dylan, Rivera Rebecca and Jose V. Torres. 
  63. Tenth Annual Cancer Research Symposium.  UCDavis Cancer Center.
  64. 2005. Epidemiology of Breast cancer in Sonora, Mexico. Márquez-Manríquez JP, Salazar L, Disis ML, Lucero-Díaz PA, Cabello-Molina R., and José V. Torres
  65. 28th CTRC-AACR San Antonio Breast Cancer Symposium.
  66. 2006. Immunomodulating Activity of Nimesulide, Meloxicam and Pidotimod in PBMCs from advanced cancer patients. Márquez-Manríquez JP, Barnes C, Castillo-Montoya V, Bayliss L, Mon A, Fernández C, Lucero-Díaz PA, Cabello-Molina R., and José V. Torres
  67. Twelveth Annual Cancer Research Symposium. UCDavis Cancer Center.
  68. 2007. Clinical Immunomodulation in Ovarian and Breast Cancer Patients. Márquez-Manríquez JP, Vella M, Lucero-Díaz PA, Cabello-Molina R., and José V. Torres
  69. 2nd Breast Cancer Symposium. UCDavis Cancer Center.
  70. 2008. Naturally Occurring Immune Responses in Ovarian and Breast Cancer Patients. Márquez-Manríquez JP, Vella M, Durazo F., and José V. Torres. 3rd Breast Cancer Research Symposium. UCDavis Cancer Center. Sacramento, CA.
  71. 2009. Study of the Immunogenicity of Bcl-2, survivin and Epidermal Growth Factor Receptor (EGFR) peptides as potential biomarkers for early breast cancer detection. Torres JV, Lopez A and Marquez JP. Center for Biophotonics Science and Technology. Sacramento, CA.
  72. 2010. Epidermal Growth Factor Receptor Synthetic Peptides and Immunomodulation Induce Immune and Clinical Responses in Advanced Ovarian Cancer Patients.  Torres  JV, Ramos E, Ostashko A, Schmidt K, Lucero-Diaz PA, Ruiz J, Durazo-Bustamante FA, Gardner M and Marquez JP.  American Association for Cancer Research (Tumor Immunology: Basic and Clinical Advances), Miami, Florida.
  73. 2010. Epidermal Growth Factor Receptor Peptides Induce Immune and Clinical Responses in Advanced Breast and Ovarian Cancer Patients.  Marquez JP, Ramos E, Vella M, Schmidt KD, Ruiz J, Durazo F, Gardner M, Salguero LA, Cabello R, Ostashko A, Liu S and Torres JV. Cancer Research Institute (CRI) Symposium, October 6-8, 2010, NY, NY.
  74. 2011. Naturally Occurring Immune Response Against Sox2 and Bcl-2 In Cancer Patients.  Marquez JP,  Durazo F, Ramos E, Cabello R, Ostashko A, Toney B, Lucero-Diaz PA, Camacho-Hernandez A, Gardner M, Maurano M and Torres JV; National Cancer Institute (NCI), Cancer Immunology & Immunotherapy: Building on success, September 22-23, 2011, Bethesda, MD.
  75. 2012. Naturally Occurring Immune Response Against Sox2 and Bcl-2 In Patients with Advanced and Ealy-stage Cancer.  Marquez JP,  Durazo F, Ramos E, Lucero-Diaz PA, Camacho-Hernandez A, Cabello R, Gardner M, Toney B, Maurano M and Torres JV; 26th Annual Scientific Meeting of the Society for Immunotherapy of Cance (SITC), Journal of Immunotherapy Vol 35; 1, 2012, p 98-99.

Oral Presentations (From More Than 50)
José V. Torres, Ph.D.

  1. Torres, J.V., Wyde, P.R. and Atassi, M.Z.  Cytotoxic T lymphocyte recognition sites on influenza virus hemagglutinin.  Fourth International Congress of Cell Biology, p.10 3.28, Montreal, Canada.  1988
  2. Torres, J.V., Wyde, P.R. and Atassi, M.Z.  Delayed type hypersensitivity response to areas at the surface of the influenza virus hemagglutinin.  Fifth International Symposium on the Immunobiology of Proteins and Peptides, 34, Alberta, Canada.  1988
  3. Torres, J.V., Pedersen, C., Oxford, C., Leung, C.Y., Werner, L.L., Malley, A. and Benjamini, E.  The induction of anti-simian retrovirus-1 (SRV-1) neutralizing antibodies by synthetic peptides.  Midwinter Conference of Immunologists, Asilomar, CA.  1989
  4. Torres, J.V., Werner, L.L., Malley, A. and Benjamini, E.  Neutralizing epitopes of Type D simian retroviruses (SRV-1 and SRV-2) and identification of the cell receptor for SRV-1.  Symposium in Non-human Primate Models for AIDS.  New Orleans, Louisiana. 1990
  5. Torres, J.V.  Neutralization epitopes of SIVmac GP130.  Center for AIDS Research Seminar, California Primate Research Center, U.C. Davis.      1992
  6. Torres, J.V.  A neutralization epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac).  Tenth Annual Symposium on Nonhuman Primate Models for AIDS.  San Juan, Puerto Rico.  1992
  7. Torres, J.V.  Viral Pathogenesis Mini Symposia.  1992
  8. Torres, J.V., Jarvis, M., Leung, N., and Gardner, M.B.  Variable neutralization epitope in the envelope glycoprotein of simian immunodeficiency virus (SIV).  American Society for Virology.  Davis, California, July 10-14.             1993
  9. Torres, J.V.  "Hypervariable epitope constructs (HECs) as a means of accounting for epitope variability".  Universitywide AIDS Research Program, 11th Annual AIDS Investigators' Meeting, San Francisco, CA, March 29-30.  1994
  10. Torres, J.V.  "Humoral and cellular responses to a HEC/rBCG combination vaccine against SIV and HIV".  Universitywide AIDS Research Program, 11th Annual AIDS Investigators' Meeting, San Francisco, CA, March 29-30.  1994
  11. Torres, J.V.  "Design and production of a combination vaccine against HIV and AIDS".  Medical Microbiology and Immunology Department Seminar, School of Medicine, U.C. Davis, April.  1994
  12. Torres, J.V.  "Molecular Biology and Immunology of HIV".  University of Puerto Rico.  May.  1994
  13. Torres, J.V. "Vaccine Strategies against HIV".  School of Medicine, Ponce, Puerto Rico.  May.  1994
  14. Torres, J.V.  "Design, development, and testing of AIDS vaccines".  University of Puerto Rico, School of Medicine, Invited General Seminar, September.  1994
  15. Torres, J.V.  "Human AIDS vaccine trials".  World Health Organization (WHO) HIV Surrogate Markers Conference, Quebec, Canada, October 23.  1994
  16. Torres, J.V.  "Combination vaccine against AIDS".  Eastern Ontario Children's Hospital, October 25.  1994
  17. Torres, J.V., Keynote Speaker: "Humoral and cellular immune responses to a combination vaccine against AIDS".  9th Congress of Scientific Research, San Juan, Puerto Rico, February 23.  1995
  18. Torres, J.V., Plenary Session Speaker:  "Design, evaluation and performance of clinical trials in the development of vaccines".  16th Annual Research Forum, Rio Piedras, Puerto Rico, March 13.  1995
  19. Torres, J.V., Plenary Lecture: "Construction of Vaccines:  The Case of AIDS".  XXVII Congreso Nacional de Ciencias Farmacéuticas, 22-26 October, Merida, Yucatan, Mexico.1995  
  20. Torres, J.V., Conference: “AIDS: Vaccine Research and Development”.  Universidad de los Andes, Facultad de Medicina, Departamento de Patologia, Merida, Venezuela, 25 July, 11:00 a.m., Auditorio Hospital.   1996
  21. Torres, J.V., Seminar: “Our new vaccine approaches and their application to HIV and AIDS”.  University of California, Davis Medical Center, September 3.  1996
  22. Torres, J.V., Seminar: “Vaccine Biotechnology”.  Hosted by Instituto Politecnico Nacional, Mexico City, Mexico, October 2. 1996
  23. Torres, J.V., “New AIDS Vaccines: Discovery, Invention, Design, Development And Testing”.  Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. October 4.       1996
  24. Torres, J.V.  Diagnosis and Treatment of AIDS. Keynote Speaker, Annual Meeting of Certified Medical Technologists, San Fernando de Apure, Venezuela, July 11.  1997
  25. Torres, J.V.  General AIDS Research Update and Vaccine Studies at my Laboratory.  Invited speaker, Faculty of Sciences, University de Los Andes, Merida, Venezuela, July 21.  1997          
  26. Torres, J.V.  Unification of Latin American Scientists and Physicians.  Invited speaker, University de Los Andes and FUNDACITE.  CLABE, Latin American Council for Biomedical Research, July 22.  1997
  27. Torres, J.V. Molecular Biology and Immunology of HIV, Invited Speaker, August 4.  1997
  28. Torres, J.V.  Strategies for the Study and Production of Vaccines Against HIV.  Invited Speaker, Unidad Professional Interdisciplinaria de Biotecnologia 10th Aniversario Meeting, Mexico City, August 5.  1997
  29. Torres, J.V.  AIDS Prevention, Merida, Venezuela, February 15, 1998
  30. Torres, J.V.  AIDS Gateway Symposium, Ponce School of Medicine, August, 1998.
  31. Torres, J.V. HIV Vaccine Development, SILCIBIO 98, Mexico, November 26, 1998
  32. Torres, J.V. AIDS Vaccines, Pathogenesis and Therapy Research.  Invited Speaker, Instituto Politecnico Nacional, School of Medicine, November 27, 1998.
  33. Torres, J.V. Development of Vaccines Against Human Pathogens that Undergo Antigenic Variation, Keynote Speaker, 5th Latin American Immunology Congress, Punta del Este, Uruguay, December 12-16, 1999
  34. Torres, J.V.  First Meeting of Molecular Sentinel Research Network. What is CLABE and how CLABE and MSRNET May Complement Each Other, Adjuntas, PR, July 22-23, 2000
  35. Torres, J.V.  Vaccine Against Viruses Associated with Human Cancer.  SILCIBIO-Nocardiae 2000.  Third Symposium of Latin American Scientists in Biomedical Research and Second International Conference on the Biology of Nocardiae.  School of Medicine.  University of California, Davis.  September 11-15, 2000
  36. Torres, J.V.  Cancer Research.  American Cancer Society, Institutional Research Grant Reception, UCD Cancer Center.  October 11, 2001
  37. Torres, J.V.  SFSU Cell Science Colloquium, November 8, 2001
  38. Torres, J.V.  Recombinant BCG as a Vector for AIDS Vaccines, International AIDS Vaccine Initiative, New York City, 2002
  39. Torres, J.V.  Cancer Induction by Human Viruses, Ciudad Obregon, Sonora, Mexico, 2002
  40. Torres, J.V.  Battles of HIV/AIDS in the lab: Past, Present and Future. American River College, 2003
  41. Torres, J.V.  Keynote Speaker, Advances Against Emerging Infectious Diseases in the Developing World, Pharmacology Congress, Cancun, Mexico, Nov 2003
  42. Viruses vs. Immune System; Who is Ahead?, Invited Seminar given at the Ponce School of Medicine, 2006
  43. Being a Scientist is a Privilege, Invited Seminar given at the Ponce School of Medicine, 2006
  44. Breast Cancer Control, UC Davis Cancer Center, October 2007
  45. Cancer Immunotherapy, January 8, 2010, MMI 208 Seminar Series, Davis CA
  46. Cancer Immunomodulation, March 1, 2011, CCM, Davis, CA

 

Jose V. Torres

Professor

 

 

  • : (530) 752-3157
  • DEPARTMENTDepartment of Medical Microbiology and Immunology
    University of California Davis
  • COUNTRY USA